NYSE:GSK GSK (GSK) Stock Price, News & Analysis $37.34 -0.34 (-0.90%) Closing price 08/5/2025 03:59 PM EasternExtended Trading$37.34 0.00 (0.00%) As of 08/5/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About GSK Stock (NYSE:GSK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GSK alerts:Sign Up Key Stats Today's Range$37.09▼$37.6750-Day Range$36.21▼$42.5052-Week Range$31.72▼$44.67Volume3.41 million shsAverage Volume6.26 million shsMarket Capitalization$76.18 billionP/E Ratio17.29Dividend Yield4.58%Price Target$37.38Consensus RatingHold Company Overview GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Read More GSK Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreGSK MarketRank™: GSK scored higher than 54% of companies evaluated by MarketBeat, and ranked 1145th out of 1,836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.1 / 5Analyst RatingHold Consensus RatingGSK has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on no buy ratings, 7 hold ratings, and 1 sell rating.Amount of Analyst CoverageGSK has only been the subject of 1 research reports in the past 90 days.Read more about GSK's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth12.32% Earnings GrowthEarnings for GSK are expected to grow by 12.32% in the coming year, from $4.14 to $4.65 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GSK is 17.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.83.Price to Earnings Ratio vs. SectorThe P/E ratio of GSK is 17.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.88.Price to Earnings Growth RatioGSK has a PEG Ratio of 1.64. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGSK has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.67% of the float of GSK has been sold short.Short Interest Ratio / Days to CoverGSK has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GSK has recently decreased by 26.97%, indicating that investor sentiment is improving significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend LeadershipGSK is a leading dividend payer. It pays a dividend yield of 4.54%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthGSK does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of GSK is 79.17%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, GSK will have a dividend payout ratio of 36.77% next year. This indicates that GSK will be able to sustain or increase its dividend.Read more about GSK's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.67% of the float of GSK has been sold short.Short Interest Ratio / Days to CoverGSK has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GSK has recently decreased by 26.97%, indicating that investor sentiment is improving significantly. News and Social Media3.1 / 5News Sentiment0.54 News SentimentGSK has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for GSK this week, compared to 20 articles on an average week.Search Interest34 people have searched for GSK on MarketBeat in the last 30 days. This is an increase of 3% compared to the previous 30 days.MarketBeat Follows6 people have added GSK to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, GSK insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.00% of the stock of GSK is held by insiders.Percentage Held by InstitutionsOnly 15.74% of the stock of GSK is held by institutions.Read more about GSK's insider trading history. Receive GSK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address GSK Stock News HeadlinesGSK’s RSV Vaccine Study: A Potential Game-Changer for Older AdultsAugust 5 at 12:42 PM | tipranks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSKAugust 5 at 10:00 AM | globenewswire.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world. | Traders Agency (Ad)GSK (NYSE:GSK) Stock Rating Upgraded by Wall Street ZenAugust 5 at 2:49 AM | americanbankingnews.comGSK’s New Phase 3 Study: A Potential Game-Changer in Lung Cancer TreatmentAugust 1, 2025 | tipranks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSKAugust 1, 2025 | globenewswire.comAnalysts Have Made A Financial Statement On GSK plc's (LON:GSK) Interim ReportAugust 1, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSKJuly 31, 2025 | prnewswire.comSee More Headlines GSK Stock Analysis - Frequently Asked Questions How have GSK shares performed this year? GSK's stock was trading at $33.82 at the beginning of the year. Since then, GSK shares have increased by 10.4% and is now trading at $37.34. How were GSK's earnings last quarter? GSK PLC Sponsored ADR (NYSE:GSK) posted its earnings results on Wednesday, July, 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.11. The firm's quarterly revenue was up 1.3% compared to the same quarter last year. Read the conference call transcript. Who are GSK's major shareholders? GSK's top institutional investors include Miller Howard Investments Inc. NY (0.08%), Douglas Lane & Associates LLC (0.06%), Bank of New York Mellon Corp (0.05%) and Sound Income Strategies LLC (0.02%). View institutional ownership trends. How do I buy shares of GSK? Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GSK own? Based on aggregate information from My MarketBeat watchlists, some other companies that GSK investors own include Chevron (CVX), BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), Bristol Myers Squibb (BMY), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Record date for 7/10 Dividend5/16/2025Ex-Dividend for 7/10 Dividend5/16/2025Dividend Payable7/10/2025Last Earnings7/30/2025Today8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSE:GSK CIK1131399 Webwww.gsk.com Phone442080475000Fax44-20-8047-7807Employees68,629Year Founded2000Price Target and Rating Average Price Target for GSK$37.38 High Price Target$39.50 Low Price Target$35.25 Potential Upside/Downside+0.1%Consensus RatingHold Rating Score (0-4)2.11 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$2.16 Trailing P/E Ratio17.29 Forward P/E Ratio9.02 P/E Growth1.64Net Income$3.29 billion Net Margins10.81% Pretax Margin14.68% Return on Equity49.22% Return on Assets11.31% Debt Debt-to-Equity Ratio1.07 Current Ratio0.87 Quick Ratio0.57 Sales & Book Value Annual Sales$40.10 billion Price / Sales1.90 Cash Flow$5.55 per share Price / Cash Flow6.73 Book Value$8.07 per share Price / Book4.63Miscellaneous Outstanding Shares2,040,290,000Free Float1,836,257,000Market Cap$76.18 billion OptionableOptionable Beta0.51 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NYSE:GSK) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.